MedTrace Logo

Tumor Control, Treatment Toxicity, Quality of Life and Bio-Imaging Repository Databank (TQ-BIRD) for Cancer Patients

NCT05061342 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 5000

Last updated 2026-01-27

No results posted yet for this study

Summary

Our central hypothesis is that patient response to treatment, evaluated by full spectrum of outcome measures including tumor control, survival, toxicity, and quality of life (QoL), will correlate with biomarker expressions, which can be tested in the blood, other body fluid, imaging as well as tumor tissue (if available).

Conditions

Interventions

OTHER

No experimental interventions 1. Observation; 2. Anticancer treatments, including surgery, systemic therapy, radiotherapy, Chinese traditional medicine, or palliative/supportive care.

Any anticancer or palliative care

Sponsors & Collaborators

  • Queen Mary Hospital, Hong Kong

    collaborator OTHER

  • Taizhou Hospital

    collaborator OTHER

  • Peking University Shenzhen Hospital

    collaborator OTHER

  • Shenzhen People's Hospital

    collaborator OTHER

  • The First Affiliated Hospital of Henan Medical University

    collaborator UNKNOWN

  • Fengming Kong

    lead OTHER

Principal Investigators

  • Feng-Ming (Spring) KONG, Professor · The University of Hong Kong-Shenzhen Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-06-27
Primary Completion
2029-12-31
Completion
2029-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05061342 on ClinicalTrials.gov